Article Sidebar

PDF
Date Published: 30/03/2023
Abstract Views: 228
Views PDF: 100
DOI: https://doi.org/10.51298/vmj.v524i2.4817
Issue
Vol. 524 No. 2 (2023)
Section
Các bài báo
How to Cite
Võ , V. X. ., Nguyễn, Q. D. ., & Vũ , X. H. . (2023). RESULTS OF TECHNICAL RADIOTHERAPY IMRT COMBINEĐAD WITH CHEMOTHERAPY IN THE NASOPHARYNX CANCER STAGE III-IVA. Vietnam Medical Journal, 524(2). https://doi.org/10.51298/vmj.v524i2.4817

RESULTS OF TECHNICAL RADIOTHERAPY IMRT COMBINEĐAD WITH CHEMOTHERAPY IN THE NASOPHARYNX CANCER STAGE III-IVA

Văn Xuân Võ 1,, Quang Duy Nguyễn1, Xuân Huy Vũ 1
1 K hospital

Main Article Content

Abstract

Objective: Evaluating response rate of concurrent chemoradiotherapy with IMRT technique in stage III-IVa nasopharyngeal carcinoma and safety profile of this regimen. Method: Descriptive, retrospective plus prospective study of 42 stage III-IVa nasopharyngeal carcinoma patients treated from April 2019 to March 2021. Results: All patients responded to treatment, of which complete response rate was 75.7%. The complete response rates in T1-T4 tumor were 100%, 87.5%, 90.9%, and 62.5%, respectively. The complete response rates in N0, N1, N2 disease were 100%, 94.7%, and 70.6%, respectively. Common hematological adverse events included grade 3 leukopenia (16.7%), grade 3 neutropenia (9.6%) and grade 4 neutropenia (2.4%). Non-hematological side effects included oral mucositis (11.6%), fatique (9.6%), and weight loss (4.8%). Conclusion: The regimen brings good response rate and safety.

Article Details

Keywords

Nasopharyngeal carcinoma, radiotherapy, chemotherapy

References

1. Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. The Lancet Oncology. 2012; 13(2):163-171.
2. Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. The Lancet Oncology. 2016; 17(11):1509-1520.
3. Nguyễn Thị Hà. Đánh giá kết quả xạ trị điều biến liều kết hợp hóa trị ung thư vòm mũi họng giai đoạn III-IVB: Luận văn Thạc sĩ y học, Trường Đại học Y Hà Nội; 2017.
4. Chen YP, Tang LL, Yang Q, et al. Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials. Clinical cancer research: an official journal of the American Association for Cancer Research. 2018; 24(8):1824-1833.
5. Lee AWM, Tung SY, Ng WT, et al. A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. Cancer. 2017;123(21):4147-4157.
6. Lê Chinh Đại. Nghiên cứu điều trị phối hợp hóa-xạ trị và xạ trị đơn thuần bệnh ung thư vòm mũi họng giai đoạn III, IV (Mo): Luân án Tiến sỹ y học, Trường Đại học Y Hà Nội; 2007.
7. Bùi Vinh Quang. Nghiên cứu điều trị ung thư vòm mũi họng giai đoạn III, IV (M0) bằng hóa xạ trị gia tốc 3 chiều (3D) theo hình dạng khối u. Luận án Tiến sỹ Y học, Trường Đại học Y Hà Nội; 2012.
8. Hoàng Đào Chinh và cộng sự. Đánh giá kết quả bước đầu xạ trị điều biến liều kết hợp hóa trị đồng thời ung thư vòm hầu giai đoạn III- IVB. Tạp chí Ung thư học 2015;2.